*
**
***
*Corresponding Address: X-5 Subhartipuram, Meerut. (U.P.) Phone: 9837360657 drmahip@hotmail.com
Asthma is characterized by a chronic airway in ûammation that may lead to airway obstruction, hyperresponsiveness, and clinical symptoms of cough, wheeze, and shortness of breath. Current asthma management guidelines recommend the use of this combination of LABA + ICS for patients who remain symptomatic on low-dose inhaled corticosteroids.
This study was conducted to evaluate the efficacy and safety of the fixed dose combination of formoterol and fluticasone in clinical practice.
It was an open - labeled surveillance study enrolling 110 patients of asthma not adequately controlled on ICS alone.
At the end of 4 week of treatment with MDI and DPI of the fixed dose combination of Formoterol and Fluticasone, study population reported a significant reduction of mean cough score by 87.9% form baseline (Baseline 2.31 Vs 0.28 at 4 week). Similarly, the mean scores for wheeze and tightness of chest reduced to 0 form baseline (a reduction of 100%). The mean score of shortness of breath also showed a significant reduction of 89.6% at the end of study period form baseline.
A fixed dose combination of formoterol + fluticasone MDI/DPI is safe and efficacious in the management of asthmatic patients not adequately controlled on inhalational corticosteroids alone in clinical practice in India.
